Galderma Group AG (XSWX:GALD) Short-Term Debt: CHF22 Mil (As of Dec. 2025)


XSWX:GALD Galderma Group AG XSWX:GALD
14 GF Score
Price CHF174.40
! 4 Warning Signs
View Full Analysis

What is Galderma Group AG Short-Term Debt?

Galderma Group AG XSWX:GALD -0.37% 14 Short-Term Debt is CHF22 Mil as of Dec. 2025. GuruFocus rates XSWX:GALD with a GF Score™ of 14/100. The stock has 4 warning signs investors should review.

Galderma Group AG's Short-Term Debt for the quarter that ended in Dec. 2025 was CHF22 Mil.

Galderma Group AG's quarterly Short-Term Debt increased from Dec. 2024 (CHF5 Mil) to Jun. 2025 (CHF16 Mil) and increased from Jun. 2025 (CHF16 Mil) to Dec. 2025 (CHF22 Mil).

Galderma Group AG's annual Short-Term Debt declined from Dec. 2023 (CHF34 Mil) to Dec. 2024 (CHF5 Mil) but then increased from Dec. 2024 (CHF5 Mil) to Dec. 2025 (CHF22 Mil).

Galderma Group AG Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Galderma Group AG Short-Term Debt Related Terms

Galderma Group AG Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Galderma Group AG's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galderma Group AG Short-Term Debt Chart

Galderma Group AG Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
0.00 0.00 33.73 5.35 21.52

Galderma Group AG Semi-Annual Data
Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Short-Term Debt Get a 7-Day Free Trial 33.73 5.36 5.35 16.26 21.52
XSWX:GALD
14GF Score
Galderma Group AG XSWX:GALD
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of CHF22 Mil mean?
Galderma Group AG (XSWX:GALD) has a Short-Term Debt of CHF22 Mil as of Dec. 2025.
Is Galderma Group AG's Short-Term Debt too high?
Galderma Group AG's current Short-Term Debt is CHF22 Mil. Overall, Galderma Group AG has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Galderma Group AG's Short-Term Debt compare to ZTS and UTHR?
Galderma Group AG's Short-Term Debt of CHF22 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Galderma Group AG's current Short-Term Debt is CHF22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galderma Group AG stock overvalued right now?
Galderma Group AG (XSWX:GALD) has a current Short-Term Debt of CHF22 Mil. The current Short-Term Debt is CHF22 Mil. Galderma Group AG's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Galderma Group AG (XSWX:GALD), the current Short-Term Debt is CHF22 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Galderma Group AG Business Description

Address Zahlerweg 10, Zug, CHE, 6300
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
14GF Score

Get the complete analysis for XSWX:GALD

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF174.40
Price